CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
hydroxychloroquinedrug
Likely dose
hydroxychloroquine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00726596
NCT00726596Phase 2Completed
CompareCT.gov

NJ 1808: Autophagic Cell Death With Hydroxychloroquine in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy For Prostate Cancer.

Rutgers, The State University of New Jersey·interventional·Posted Aug 1, 2008·Updated Jun 16, 2022

In Brief

A Phase 2 clinical trial evaluating hydroxychloroquine for Prostate Cancer. Completed, enrolled 64 participants across 5 sites.

Detailed Summary

This phase II trial studies how well hydroxychloroquine works in treating patients with previously treated prostate cancer. Autophagy destroys proteins and other substances in cells and may be used by prostate cancer cells to survive. Hydroxychloroquine, which blocks autophagy, may slow the growth of and possibly kill prostate cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsRutgers Cancer Institute of New Jersey, National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 1, 2008
Enrollment StartAug 1, 2008
Primary CompletionFeb 1, 2014
Study CompletionJan 1, 2018
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 17.9 years ago

Interventions

hydroxychloroquinedrug

Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).